For private equity sponsors and operators of clinical research site networks

Site networks add studies, locations, investigators and therapeutic areas. Startup speed, enrollment, capacity, margin and cash do not move with them.

The constraint is rarely one workflow or one technology. It is the interaction among portfolio selection, sponsor requirements, patient access, investigator capacity and local operating practice.

What grows Studies · sites · investigators · coordinators · therapeutic areas · sponsors
What should follow Faster activation · predictable enrollment · more delivery capacity · cleaner data · collected cash · reusable capability
Six leverage domains Where scale should create leverage, and why it usually does not.
Study portfolio and feasibility
Better study selection and stronger protocol fit.
Feasibility stays reactive, disconnected from capacity and economics.
Study startup and activation
Repeatable contracting, budgeting and site readiness.
Requirements vary and local teams rebuild the same process.
Recruitment and enrollment
Predictable conversion, enrollment and retention.
Referrals, outreach, prescreening and follow-up stay disconnected.
Investigator and coordinator time
More productive study delivery per scarce hour.
Protocol burden, training and uneven study allocation rise with volume.
Execution and sponsor performance
Consistent delivery and cleaner data.
Workflows, definitions and escalation thresholds vary by site.
Revenue realization and integration
Accurate billing and timely cash.
Milestone capture, invoicing and operating standards remain local.
The answer is not automatically more technology
The right intervention may be simplification, standardization, a shared capability, better system linkage, conventional automation or selective AI. The objective is the simplest intervention capable of changing the economics.
SCALED · how far the intervention should go An organization may stop at any stage.
S Simplify→ C Codify→ A Aggregate→ L Link→ E Execute automatically→ D Deploy AI selectively
Two decades inside regulated healthcare operations: 30+ regulated products shipped, P&L-owner. Ex-LabCorp, Deployed systems to the VA, NHS, Memorial Sloan-Kettering.
Start with one site network
Select one consequential question involving startup, enrollment, investigator capacity, sponsor performance, margin, cash or integration. A preliminary conversation determines whether it warrants a diagnostic.
Discuss a clinical research value-creation question →
Arvita Tripati
Value Creation Advisor & CEO, Vahana Labs
arvita@vahanalabs.ai